Scynexis SCYX 深 沪
等待开盘 11-12 09:30:00 美东时间
3.415
-0.105
-2.98%
华盛通- 最 高3.6698
- 今 开3.62
- 成交量 6.22万股
- 最 低 3.37
- 昨 收 3.52
- 总市值 3399.00万
- 52周最高 9.12
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 3.2801
- 委 比 87.64%
- 总股本 995.32万
- 历史最高 1200.00
- 量 比 1.16
- 振 幅 8.52%
- 历史最低 3.2801
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SCYNEXIS Q3 EPS $(0.71) Beats $(0.72) Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.72) by 1.39 percent. This is a 47.79 percent increase over losses of $(1.36) per share from the same period last year.
11-05 21:21
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
SCYNEXIS, Inc. announced that its second-generation triterpenoid antifungal candidate, SCY-247, will be featured in an oral presentation at IDWeek 2026. SCY-247 is being developed for the treatment and prevention of invasive fungal infections, including those caused by drug-resistant fungi, in both oral and IV formulations. The presentation, titled "SCY-247, a novel phase 2 IV/oral triterpenoid antifungal," will be delivered by David Angulo, M.D....
10-21 20:05
SCYNEXIS Completes Phase 1 Study Of SCY-770, Selective And Direct AMP-Activated Protein Kinase Activator
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated • Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026 • SCY-770 is a potential first-in-class oral direct ...
10-06 19:31
美股前瞻 | 存储重回风口！高盛唱多闪迪，海力士董事长警告“存储荒”；苹果携手阿里开发中国市场专属大模型
存储重回风口？高盛唱多后，闪迪盘前涨逾7%！海力士董事长警告“存储荒”；苹果携手阿里开发中国市场专属大模型；今晚20:30！美国7月零售销售数据压轴登场>>
08-14 20:25
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33
Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and raises the price target from $24 to $33.
08-13 22:14
SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $(0.64) by 198.44 percent. This is a 156.25 percent increase over losses of $(1.12) per share from the same period last year. The company reported quarterly sales of $235.000 thousand w...
08-11 04:45
AutoZone, Zscaler And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, SCYNEXIS, Box, and Zscaler after the closing bell.
05-26 14:13
SCYNEXIS Announces 1-For-8 Reverse Stock Split, Effective May 29
SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its
05-23 04:16
SCYNEXIS Q1 EPS $(0.42) Misses $(0.12) Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.12) by 281.82 percent. This is a 281.82 percent decrease over losses of $(0.11) per share from the
05-12 04:34
